Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS. Charities said the announcement was “another frustrating setback” for people affected by Alzheimer’s disease, describing the decision as “incredibly disappointing”. Hilary Evans-Newton, the chief executive at Alzheimer’s Research UK, urged Wes Streeting to “break the deadlock we’re facing, …
